Precision BioSciences, Inc. (DTIL)
4.92
-0.09
(-1.80%)
USD |
NASDAQ |
Dec 11, 16:00
4.92
0.00 (0.00%)
After-Hours: 17:48
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 65.22M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -12.87% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 70.76 |
| Price to Book Value | 3.921 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.751 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.20% |
Profile
| Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC. |
| URL | http://www.precisionbiosciences.com |
| Investor Relations URL | https://investor.precisionbiosciences.com/ |
| HQ State/Province | North Carolina |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 31, 2026 (est.) |
| Last Earnings Release | Nov. 03, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC. |
| URL | http://www.precisionbiosciences.com |
| Investor Relations URL | https://investor.precisionbiosciences.com/ |
| HQ State/Province | North Carolina |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 31, 2026 (est.) |
| Last Earnings Release | Nov. 03, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |